ReviewEuropean child & adolescent psychiatry2013
Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.
Review in European child & adolescent psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03708614 (A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder (ASD) While on Atypical Antipsychotic Medication
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Drugs used in psychiatry causing an increase in body weight in children-a review.International journal of obesity (2005) · 2025Pooled it
- Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder.European journal of clinical pharmacology · 2018Pooled it
- The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety · 2014Pooled it
- Weight mitigation and tolerability of adjunctive topiramate in acute pediatric psychiatry: a retrospective real-world analysis.Frontiers in psychiatry · 2026Article
- Development and Evaluation of the "Eating More Consciously" Module of a Lifestyle Intervention Program to Prevent Medication-Induced Weight Gain in Psychiatric Patients: A One-Arm Pilot Study.Alpha psychiatry · 2024Article
- Gut microbiome profiles may be related to atypical antipsychotic associated overweight in Asian children with psychiatric disorder: a preliminary study.Frontiers in cellular and infection microbiology · 2023Article
- Obesity II: Establishing causal links between chemical exposures and obesity.Biochemical pharmacology · 2022Review
- Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.Journal of psychopharmacology (Oxford, England) · 2021Article
- Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de Deuxième Génération, Cinq ans Après la publication des Lignes Directrices Camesa: Faisons-Nous des Progrès?Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Article
- Article
- Article
- Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study.BMC psychiatry · 2021Article
- CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.Frontiers in psychology · 2021Article
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
- Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments.International journal of developmental disabilities · 2019Review
- The effects of antipsychotic medications on microbiome and weight gain in children and adolescents.BMC medicine · 2019Review
- Obesity in Adolescents with Psychiatric Disorders.Current psychiatry reports · 2019Review
- Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia.Schizophrenia bulletin · 2018Article
- Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment.International review of psychiatry (Abingdon, England) · 2018Review
- Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed an updated review of the available literature on weight gain and increase of body mass index (BMI) among children and adolescents treated with antipsychotic medications. A PubMed search was conducted specifying the following MeSH terms: (antipsychotic agents) hedged with (weight gain) or (body mass index). We selected 127 reports, including 71 intervention trials, 42 observational studies and 14 literature reviews. Second-generation antipsychotics (SGAs), in comparison with first-generation antipsychotics, are associated with a greater risk for antipsychotic-induced weight gain although this oversimplification should be clarified by distinguishing across different antipsychotic drugs. Among SGAs, olanzapine appears to cause the most significant weight gain, while ziprasidone seems to cause the least. Antipsychotic-induced BMI increase appears to remain regardless of the specific psychotropic co-treatment. Children and adolescents seem to be at a greater risk than adults for antipsychotic-induced weight gain; and the younger the child, the higher the risk. Genetic or environmental factors related to antipsychotic-induced weight gain among children and adolescents are mostly unknown, although certain genetic factors related to serotonin receptors or hormones such as leptin, adiponectin or melanocortin may be involved. Strategies to reduce this antipsychotic side effect include switching to another antipsychotic drug, lowering the dosage or initiating treatment with metformin or topiramate, as well as non-pharmacological interventions. Future research should avoid some methodological limitations such as not accounting for age- and sex-adjusted BMI (zBMI), small sample size, short period of treatment, great heterogeneity of diagnoses and confounding by indication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.